• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates

Amgen

MedTech 100 roundup: Industry skies to all-time high

April 19, 2021 By Sean Whooley

The medtech industry hit a slight lull in the early stages of 2021 and, after signs of a rebound, it has soared beyond levels ever before seen. MassDevice‘s MedTech 100 Index had been building up steam in the month of April, rising from 102.16 points at the beginning of March all the way to 109.39 to […]

Filed Under: Business/Financial News, Featured, Funding Roundup, Initial Public Offering (IPO), MassDevice Earnings Roundup, Mergers & Acquisitions, Wall Street Beat Tagged With: Align Technology, Amgen, DiaSorin, Five Prime Therapeutics, Luminex, Medline Industries Inc., MedTech 100 Index, Microsoft, Nuance Communications Inc., Siemens Healthineers, Thermo Fisher Scientific, Varian Medical Systems, Vicarious Surgical

Amgen completes $1.9B acquisition of Five Prime Therapeutics

April 16, 2021 By Sean Whooley

Amgen (NSDQ:AMGN) announced today that it completed its $1.9 billion acquisition of Five Prime Therapeutics (NSDQ:FPRX). Thousand Oaks, Calif.-based Amgen has officially acquired South San Francisco-based Five Prime for $38 per share in cash, reaching an equity value of approximately $1.9 billion. The acquisition was initially announced on March 4, 2021. Get the full story at our sister […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Mergers & Acquisitions, Oncology, Pharmaceutical Tagged With: Amgen, Five Prime Therapeutics

MedTech 100 roundup: Industry sees largest fall since October

March 8, 2021 By Sean Whooley

The medtech industry’s hot start to 2021 has finally come to a full halt after stocks fell harder than they had in more than four months. MassDevice‘s MedTech 100 index ended the week (March 5) at 103.3 points, marking a -3.1% dip from the 106.65-point mark set one week before (Feb. 26). In less than a […]

Filed Under: Business/Financial News, Featured, MassDevice Earnings Roundup, Mergers & Acquisitions, Wall Street Beat Tagged With: Amgen, Asensus Surgical, BD, becton dickinson, Boston Scientific, Colfax Corp., conformis, coronavirus, COVID-19, Five Prime Therapeutics, GSL Solutions, Hillrom, LivaNova, MedTech 100 Index, Medtronic, Permira, Senseonics, TransEnterix

Amgen to acquire Five Prime Therapeutics for $1.9B

March 4, 2021 By Sean Whooley

Amgen (NSDQ:AMGN) announced today that it is set to acquire Five Prime Therapeutics (NSDQ:FPRX) for approximately $1.9 billion. Thousand Oaks, Calif.-based Amgen will acquire South San Francisco-based Five Prime for $38 per share in cash, reaching the equity value of approximately $1.9 billion, according to a news release. Get the full story at our sister site, Drug Delivery […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Mergers & Acquisitions, Oncology, Pharmaceutical Tagged With: Amgen, Five Prime Therapeutics

Pharma stocks fall as Rep. Cummings launches drug pricing investigation

January 14, 2019 By Sarah Faulkner

Chairman of the House Oversight Committee Rep. Elijah Cummings (D-MD) launched an investigation today into the drug pricing practices of 12 pharmaceutical companies. A number of companies named in the investigation saw their stock prices fall, including Amgen (NSDQ:AMGN), AbbVie (NYSE:ABBV), AstraZeneca (NYSE:AZN), Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO). A hearing is reportedly set for Jan. 29 and will include patients affected by rising […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Pharmaceutical, Wall Street Beat Tagged With: AbbVie, Amgen, AstraZeneca plc, Eli Lilly & Co., Novo Nordisk, Sanofi-Aventis

Amgen touts lowered prices for Repatha delivery devices

January 8, 2019 By Sarah Faulkner

Amgen (NSDQ:AMGN) said today that it lowered the list prices of the drug-delivery devices for its cholesterol drug, Repatha, to $5,850 per year. The Thousand Oaks, Calif.-based company touted the 60% discount as a way to boost patient affordability and accessibility. Get the full story at our sister site, Drug Delivery Business News.

Filed Under: Business/Financial News, Cardiovascular, Drug-Device Combinations, Featured, Pharmaceutical, Wall Street Beat Tagged With: Amgen

Teva wins FDA nod for migraine prevention drug

September 17, 2018 By Sarah Faulkner

Teva (NYSE:TEVA) last week won FDA approval for its humanized monoclonal antibody, Ajovy, designed to prevent migraines. The treatment, which blocks the receptor for a protein that is linked to migraine pain, is available in quarterly and monthly-injection options. Amgen‘s (NSDQ:AMGN) competitive once-monthly product won FDA approval earlier this year. Get the full story at our sister site, […]

Filed Under: Featured, Food & Drug Administration (FDA), Neurological, Pharmaceutical, Regulatory/Compliance, Wall Street Beat Tagged With: Amgen, Teva Pharmaceuticals

EMA committee recommends approval for migraine prevention drug

June 1, 2018 By Sarah Faulkner

Novartis (NYSE:NVS) said today that a committee for the European Medicines Agency has recommended that the regulatory agency approve Aimovig, a self-administered drug designed to prevent migraines in adults who have at least four migraine days each month. The drug is the first of a new class of medicines, called CGRP inhibitors. It’s a monoclonal antibody […]

Filed Under: Drug-Device Combinations, Neurological, Pharmaceutical, Regulatory/Compliance, Wall Street Beat Tagged With: Amgen, Novartis

With groundbreaking approval, Amgen launches new class of medicine for migraine patients

May 18, 2018 By Sarah Faulkner

Amgen (NSDQ:AMGN) won FDA approval this week for its once-monthly Aimovig injection designed to prevent the onset of migraines in adults. The drug is the first of its kind – a molecule that blocks the receptor for a protein that is linked to migraine pain, the calcitronin gene-related peptide. Other major pharmaceutical companies like Eli Lilly (NYSE:LLY) […]

Filed Under: Drug-Device Combinations, Food & Drug Administration (FDA), Neurological, Pharmaceutical, Regulatory/Compliance, Wall Street Beat Tagged With: Amgen, Eli Lilly & Co., Teva Pharmaceuticals

EMA committee backs Amgen’s on-body injector for Neulasta

February 27, 2018 By Sarah Faulkner

Amgen (NSDQ:AMGN) said today that a committee for the European Medicines Agency has recommended that the regulatory body approve a label variation for its Neulasta product to include the Onpro on-body injector delivery device. Neulasta’s Onpro kit includes a pre-filled syringe paired with a single-use on-body injector. The lightweight device is given to the patient on the […]

Filed Under: Drug-Device Combinations, Oncology, Pharmaceutical, Regulatory/Compliance, Wall Street Beat Tagged With: Amgen

Amgen swings to a loss in Q4 after $6B hit from tax reform

February 2, 2018 By Sarah Faulkner

Shares in Amgen (NSDQ:AMGN) rose slightly today after the biotech missed expectations on Wall Street with its fourth-quarter earnings, but topped EPS estimates for the year ahead. The Thousand Oaks, Calif.-based company swung to a net loss in Q4 thanks to a $6 billion tax charge, posting -$4.26 billion on sales of $5.8 billion in the 3 […]

Filed Under: Biotech, Drug-Device Combinations, MassDevice Earnings Roundup, Pharmaceutical, Wall Street Beat Tagged With: Amgen

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Interim pages omitted …
  • Go to page 5
  • Go to Next Page »

Primary Sidebar

DeviceTalks Weekly

May 13, 2022
Our Pre-Post-DeviceTalks Boston episode, also MedtronicTalks replay with Gastro CMO Austin Chiang
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS